In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis

Liraglutide is a human glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. It is based on human GLP-1 with the addition of a 16-carbon fatty acid, which facilitates binding to plasma proteins, thus prolonging the elimination half-life and allowing once-daily admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Plum, Anne, Jensen, Lisbeth Bjerring, Kristensen, Jesper Bøggild
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2013
Materias:
Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838623/
https://www.ncbi.nlm.nih.gov/pubmed/23853127
http://dx.doi.org/10.1002/jps.23648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838623/
https://www.ncbi.nlm.nih.gov/pubmed/23853127
http://dx.doi.org/10.1002/jps.23648

Ejemplares similares